BeiGene
BGNE
#881
Rank
โ‚ฌ20.01 B
Marketcap
182,28ย โ‚ฌ
Share price
1.71%
Change (1 day)
0.79%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : โ‚ฌ2.11 B

According to BeiGene 's latest financial reports the company's total liabilities are โ‚ฌ2.11 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31โ‚ฌ2.05 B10.26%
2022-12-31โ‚ฌ1.86 B-11.9%
2021-12-31โ‚ฌ2.11 B49.11%
2020-12-31โ‚ฌ1.41 B150.89%
2019-12-31โ‚ฌ0.56 B30.39%
2018-12-31โ‚ฌ0.43 B43.43%
2017-12-31โ‚ฌ0.30 B500.24%
2016-12-31โ‚ฌ50.29 M29.37%
2015-12-31โ‚ฌ38.87 M69.92%
2014-12-31โ‚ฌ22.88 M-37.44%
2013-12-31โ‚ฌ36.57 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚ฌ10.97 M-99.48%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.52 B-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA